Cargando…
Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration
Treatment options for people living with amyotrophic lateral sclerosis (ALS) are limited and ineffective. Recently, dexpramipexole (RPPX) was advanced into human ALS clinical trials. In the current studies, we investigated RPPX in two parallel screening systems: 1) appropriately powered, sibling-mat...
Autores principales: | Vieira, Fernando G., LaDow, Eva, Moreno, Andy, Kidd, Joshua D., Levine, Beth, Thompson, Kenneth, Gill, Alan, Finkbeiner, Steven, Perrin, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272269/ https://www.ncbi.nlm.nih.gov/pubmed/25526593 http://dx.doi.org/10.1371/journal.pone.0091608 |
Ejemplares similares
-
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
por: Vieira, Fernando G., et al.
Publicado: (2017) -
No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS
por: Gill, Alan, et al.
Publicado: (2009) -
Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
por: Corcia, Philippe, et al.
Publicado: (2012) -
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS
por: Vieira, Fernando G., et al.
Publicado: (2015) -
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)